Opinion|Videos|January 23, 2025
Endocrine Sensitivity and the Prognostic and Clinical Implications
Author(s)Katherine Clifton, MD, Shipra Gandhi, MD
Dr. Gandhi and Dr. Clifton explore the prevalence and mechanisms of resistance to first-line endocrine therapy combined with CDK4/6 inhibitors in hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What proportion of patients with HR+/HER2– breast cancer experience resistance to first-line endocrine therapy plus CDK4/6 inhibitor?
- What are some of the mechanisms of resistance that can emerge following endocrine therapy and CDK4/6 inhibitors in HR+/HER2– breast cancer?
- How you think about endocrine resistance in the post-CDK4/6 setting? What signals—clinical, molecular, or otherwise—influence your treatment sequencing decisions?
- How does treatment resistance after first-line treatment create challenges in selecting second-line therapies?
Advertisement
Related to this article
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
3
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
4
The OncFive: Top Oncology Articles for the Week of 8/30
5